GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » ROE %

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) ROE % : -47.44% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Fresh Tracks Therapeutics's annualized net income for the quarter that ended in Dec. 2023 was $-4.95 Mil. Fresh Tracks Therapeutics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $10.44 Mil. Therefore, Fresh Tracks Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -47.44%.

The historical rank and industry rank for Fresh Tracks Therapeutics's ROE % or its related term are showing as below:

FRTX' s ROE % Range Over the Past 10 Years
Min: -151.7   Med: -47.8   Max: -18.99
Current: -61.98

During the past 13 years, Fresh Tracks Therapeutics's highest ROE % was -18.99%. The lowest was -151.70%. And the median was -47.80%.

FRTX's ROE % is ranked worse than
61.31% of 1362 companies
in the Biotechnology industry
Industry Median: -44.085 vs FRTX: -61.98

Fresh Tracks Therapeutics ROE % Historical Data

The historical data trend for Fresh Tracks Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics ROE % Chart

Fresh Tracks Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -84.76 -120.50 -151.70 -131.47 -66.50

Fresh Tracks Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.64 -200.52 -102.32 88.87 -47.44

Competitive Comparison of Fresh Tracks Therapeutics's ROE %

For the Biotechnology subindustry, Fresh Tracks Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh Tracks Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's ROE % falls into.



Fresh Tracks Therapeutics ROE % Calculation

Fresh Tracks Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-5.694/( (7.194+9.93)/ 2 )
=-5.694/8.562
=-66.50 %

Fresh Tracks Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-4.952/( (10.949+9.93)/ 2 )
=-4.952/10.4395
=-47.44 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Fresh Tracks Therapeutics  (OTCPK:FRTX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-4.952/10.4395
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.952 / 0)*(0 / 12.3215)*(12.3215 / 10.4395)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1803
=ROA %*Equity Multiplier
=N/A %*1.1803
=-47.44 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-4.952/10.4395
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.952 / -4.952) * (-4.952 / -6.608) * (-6.608 / 0) * (0 / 12.3215) * (12.3215 / 10.4395)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.7494 * N/A % * 0 * 1.1803
=-47.44 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Fresh Tracks Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301
Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.
Executives
Monica E. Luchi officer: Chief Medical Officer 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy officer: General Counsel and CCO C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha officer: Chief Research & Dev. Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant director 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton officer: Chief Accounting Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown director, officer: Chief Executive Officer 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer officer: COO and Secretary 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru director C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii officer: Chief Financial Officer
Gary A Lyons director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja officer: Chief Medical Officer 121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy officer: Chief Business Officer C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju director 5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers officer: Chief Financial Officer 3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Headlines

From GuruFocus

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

By Stock market mentor Stock market mentor 01-27-2023